Search
Paclitaxel Treatment Options
A collection of 2051 research studies where Paclitaxel is the interventional treatment. These studies are located in the United States . Paclitaxel is used for conditions such as Breast Cancer, Ovarian Cancer and Non-Small Cell Lung Cancer.
1081 - 1092 of 2051
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Trial
Buy Retatrutide Online Through Celia
Recruiting
Retatrutide (formerly M25) is an investigational peptide being studied for its potential in supporting weight management and metabolic health. It acts on GLP-1, GIP, and glucagon receptors to influence appetite, energy regulation, and fat metabolism.
Conditions:
Healthy
Featured Offer
Lose 20% of Body Weight With GLP-1's
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to tirzepatide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).
Get $50 off your first order using promo code: policy-lab-50
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).
Get $50 off your first order using promo code: policy-lab-50
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Birth Control Clinical Research Study
Recruiting
Living with obesity and looking for a birth control option that is right for you? Clinical trials are now enrolling women with a body mass index (BMI) of 30 or more in the area to help study a potential new progestin-only contraceptive patch. Participating in research studies can help advance birth control options. Don’t let financial stress hold you back. All study-related assessments, care, and study patch are available at no cost. You may also be reimbursed for study-related travel.
Conditions:
Obesity
Overweight
Overweight and Obesity
Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer
Completed
Dose Finding and Efficacy Evaluation of DOXIL (Doxorubicin HCL Liposome Injection) in Combination with Abraxane (Abraxane) in Patients with Metastatic Breast Cancer (MBC) \[Phase I and II\]
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/22/2020
Locations: Clinical Trials Research Unit, West Virginia University, Morgantown, West Virginia
Conditions: Metastatic Breast Cancer
Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers
Completed
The purpose of this study is to test the safety and effectiveness of albumin-bound paclitaxel plus gemcitabine in patients with advanced squamous cell lung cancers. The investigators would like to determine the percentage of patients with squamous cell lung cancers who experience shrinkage of their tumors following treatment with this regimen. This combination of drugs is not a standard therapy for patients with squamous cell lung cancers. However, each of these drugs, when given alone or with o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/21/2020
Locations: Miami Cancer Institute Baptist Health South Florida, Miami, Florida +5 locations
Conditions: Lung Cancer, Untreated Stage IV or Recurrent Squamous Cell Lung Cancers
ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer
Terminated
The purpose of this study is to determine if adding ASA404 to standard chemotherapy makes the cancer treatment more effective in patients with advanced lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2020
Locations: University of South Alabama/Mitchell Cancer Institute, Mobile, Alabama +248 locations
Conditions: Non-Small Cell Lung Cancer
A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer
Completed
The primary purpose of this study is to identify the maximum tolerated dose (MTD) of both intravenous and oral panobinostat when given in combination with trastuzumab and paclitaxel. The study will evaluate safety and efficacy of the combination in adult female patients with HER2+ metastatic breast cancer
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/16/2020
Locations: Novartis Investigative Site, Mobile, Alabama +6 locations
Conditions: HER-2 Positive Breast Cancer, Metastatic Breast Cancer
A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors
Completed
This is a dose escalation study that will assess the safety and efficacy of LCL161 in combination with weekly paclitaxel in adult patients with advanced solid tumors.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
12/16/2020
Locations: Dana Farber Cancer Institute SC, Boston, Massachusetts +6 locations
Conditions: Solid Tumors
Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)
Completed
To study the safety and efficacy of the combination of LJM716 and BYL719 against currently available treatments of physician's choice in previously treated esophageal squamous cell carcinoma patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2020
Locations: University of Chicago Medical Center Dept of Onc, Chicago, Illinois +12 locations
Conditions: Esophageal Squamous Cell Carcinoma
Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)
Completed
This is a phase 3 study to evaluate the efficacy of ibrutinib in combination with nab-paclitaxel and gemcitabine for the first line treatment of patients with metastatic pancreatic adenocarcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/07/2020
Locations: Oncology Specialties, PC; Clearview Cancer Institute, Huntsville, Alabama +85 locations
Conditions: Metastatic Pancreatic Adenocarcinoma
A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer
Completed
Dose escalation part:to determine the highest dose of BYL719 administered on a daily basis when given in combination with weekly paclitaxel Dose escalation part: to confirm the safety and tolerability of the BYL719 and paclitaxel combination
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/04/2020
Locations: Highlands Oncology Group, Fayetteville, Arkansas +4 locations
Conditions: Neoplasms, Breast Neoplasms, Head and Neck Neoplasms
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer
Terminated
The purpose of this study is to evaluate the dose, antitumor activity, safety and pharmacology of MEDI-575 in combination with carboplatin/paclitaxel in subjects with previously untreated, advanced non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
12/01/2020
Locations: Research Site, Fountain Valley, California +28 locations
Conditions: Non-small Cell Lung Cancer
A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.
Terminated
This is a randomized, open-label, multinational, phase III study in women with histologically- or cytologically-confirmed advanced NSCLC who are chemotherapy naïve and have PS 2. Study drug will be administered on day 1 of each 21 day cycle
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/23/2020
Locations: Desert Oasis Cancer Center, Casa Grande, Arizona +142 locations
Conditions: NSCLC
Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response
Completed
The need to understand LABC is especially compelling in populations and countries with limited resources, where breast cancer incidence is relatively low, but mortality is comparably high. In these settings access to appropriate cancer care is characteristically limited or often plainly nonexistent. In contrast to economically developed nations, where on average fewer than 20% of women present with breast cancer at advanced stages, LABC and metastatic disease are the most common stages at presen... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/19/2020
Locations: NYU Langone Medical Center, New York, New York
Conditions: Breast Cancer
Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
Completed
The purpose of this study is to evaluate the safety and efficacy of the addition of veliparib plus carboplatin and paclitaxel versus the addition of placebo plus carboplatin and paclitaxel in adults with advanced or metastatic squamous non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
11/13/2020
Locations: Northeast Arkansas Clinical Ch /ID# 128071, Jonesboro, Arkansas +224 locations
Conditions: Squamous Non-Small Cell Lung Cancer
1081 - 1092 of 2051